- In January 2025, Medtronic plc, a global leader in medical technology, announced the commercial launch of its Intellis Neurostimulator with AI-powered closed-loop capabilities in the United States and Europe. This next-generation spinal cord stimulator features real-time, adaptive therapy adjustments based on patient activity and posture, enhancing personalized pain management. The device also includes advanced data analytics and remote programming features, providing clinicians with deeper insights into patient outcomes and device performance
- In October 2024, Boston Scientific Corporation presented its latest neuromodulation innovations at the North American Neuromodulation Society (NANS) 2024 Annual Meeting, including its WaveWriter Alpha SCS System, which combines multiple waveforms for customized pain relief, and its Vercise Genus DBS System, designed for advanced Parkinson’s disease management. The company also shared pivotal clinical data highlighting the long-term benefits of these devices in improving patient mobility and reducing chronic pain
- In September 2024, NEVRO Corp unveiled its new HFX iQ Spinal Cord Stimulation System at the International Neuromodulation Society (INS) Congress. The HFX iQ system is the world’s first AI-powered spinal cord stimulator, leveraging machine learning algorithms to optimize stimulation settings based on real-time patient feedback, providing personalized and precise pain relief for chronic pain sufferers
- In September 2024, Inspire Medical Systems, Inc. announced the successful completion of its first-in-human trials for the Inspire Airway Neuromodulation System, a groundbreaking treatment for obstructive sleep apnea (OSA). The system is designed to reduce airway collapse during sleep by stimulating the hypoglossal nerve, providing an effective, non-pharmacological alternative for OSA patients who cannot tolerate continuous positive airway pressure (CPAP) therapy. The commercial launch is planned for Q1 2025
